Rain Oncology Inc
RAIN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.02M
Close$
$-1.23
292.6% downside
Current Fair Value
292.6% downsideOvervalued by 292.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.02 Million |
|---|---|
| Enterprise Value | $5.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.2 |
| Beta | -0.22 |
| Outstanding Shares | 7,829,921 |
Return
| Return on Equity | 96.76% |
|---|---|
| Return on Assets | -487.41% |
| Return on Invested Capital | 93.64% |
Valuation & Multiples
| P/E Ratio | -0.44 |
|---|---|
| PEG | -0.18 |
| Price to Sales | - |
| Price to Book Ratio | -0.32 |
| Enterprise Value to Revenue | 484.93 |
| Enterprise Value to EBIT | -0.49 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.52%▼ 0.87% |
|---|---|
| Total Invested | $1.87M▼ 23.48% |
| Investors Holding | 16▼ 1.00% |
ESG Score
No data
About Rain Therapeutics Inc
4 employees
CEO: Randall Seidl Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes usi...